Medi-Dia s.r.o.

The Medi-Dia s.r.o. team is conducting studies that address Cardiovascular Diseases, focusing on patients with atherosclerotic disease and high cardiovascular risk. The work evaluates how new therapies can lower heart‑related events and improve survival.

• Assessment of cardiovascular morbidity and mortality
• Evaluation of major adverse cardiovascular events (MACE)
• Combination of glucose‑lowering agents with standard of care

These investigations aim to provide safer, more effective options for individuals at risk of heart attacks, strokes, and related complications.

Research at the site targets Nutritional and Metabolic Diseases, especially Obesity and overweight conditions. Trials test novel compounds for weight reduction and metabolic improvement in adults struggling with excess body weight.

• Measurement of body‑weight change over time
• Evaluation of safety and tolerability of weight‑loss agents
• Impact on metabolic parameters such as insulin sensitivity

The goal is to expand therapeutic choices that help patients achieve sustainable weight loss and better health outcomes.

The department also explores Type 2 Diabetes Mellitus together with cardiovascular risk, studying how emerging drugs influence both blood‑sugar control and heart health. These studies compare new agents with existing treatments to determine relative benefits.

• Improvement in glycemic control
• Reduction of cardiovascular events in diabetic patients
• Comparative effectiveness of weekly injectable therapies

By linking glucose management with cardiovascular safety, the research seeks to deliver comprehensive treatment strategies for people living with diabetes.